Resources

Title Type
Adalimumab Induces and Maintains Mucosal Healing in CD patients (EXTEND trial results)

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn’s Disease: Data From the EXTEND Trial

Anti-TNFs for induction of remission in CD (Cochrane review)

Cochrane meta-analysis of anti-TNF therapies for induction of remission in Crohn's disease

Anti-TNFs for maintenance of remission in CD (Cochrane review)

Cochrane meta-analysis of anti-TNF therapies for maintenance of remission in Crohn's disease

Appendectomy is followed by increased risk of Crohn's disease

Chart showing cumulated risk of Crohn's disease among case patients that were subjected to appendectomy before the age of 10 years

Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis

Meta-analysis evaluating the efficacy and safety of purine analogs (azathioprine, 6-mercaptopurine (6-MP)) in the prevention of postoperative recurrence in Crohn's disease.

Bristol Stool Scale

Medical aid designed to classify the form of human faeces into seven categories. Sometimes referred to in the UK as the Meyers scale.

Budesonide for induction of remission in Crohn's disease (Cochrane Review)

Cochrane meta-analysis on budesonide for induction of remission in Crohn's disease

Budesonide for maintenance of remission in Crohn's disease (Cochrane review)

Cochrane meta-analysis of budesonide for maintenance of remission in Crohn's disease

Clinical course in Crohn’s disease (IBSEN study)

Shows four predefined curves reflecting different patterns of CD in terms of the severity of bowel symptoms from diagnosis to 10-year follow-up, and percentage of patients in IBSEN source study whose symptoms matched this disease course

Comparison of step-up vs. top-down (SUTD) treatment strategies

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Discontinuation of infliximab in Crohn's disease patients in stable remission (STORI trial)

Approximately 50% of patients with Crohn's disease who were treated for at least 1 year with infliximab and an antimetabolite agent experienced a relapse within 1 year after discontinuation of infliximab. However, patients with a low risk of relapse can be identified using a combination of clinical and biologic markers.

Effects of cigarette smoking on the long-term course of Crohn's disease

Smoking status & increased risk of requiring immunosuppressive therapy & surgery in Crohn's disease

Factors determining recurrence of Crohn’s disease after surgeryMost Crohn’s disease patients will require surgery. Source: National Cooperative Crohn’s Disease Study: Factors determining recurrence of Crohn’s disease after surgery
Frequency of fistulae in relation to Crohn's disease duration
Grading of disease activity in Crohn's disease

Grading of disease activity in Crohn's disease

How to interpret values in patients failing anti-TNF therapy2x2 matrix showing four scenarios encountered in patients with insufficient clinical response to anti-TNF antibody drugs.
Incidence rates of Crohn's disease in 20 European centres
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Meta-analysis suggesting an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP. This could be a result of the medications, the severity of the underlying disease, or a combination of the two.

Infectious agents causing an episode of infectious gastroenteritis could play a role in the initiation of IBD

Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease

Influence of age at diagnosis on site and clinical type of Crohn's disease

At diagnosis, small bowel disease is more frequent in younger patients while colonic disease is more frequent in older patients

Long-term Evolution of Disease Behavior in Crohn's Disease

Kaplan-Meier estimates of remaining free of penetrating and/or stricturing complications since onset (diagnosis) of the disease.

Mayo Score

Extract from ECCO UC consensus, showing Mayo Score

Montreal Classification

Overview of Montreal Classification

Montréal classification

Extract from ECCO UC consensus, showing Montréal classification of disease activity

MUSIC: mucosal healing in patients with moderate to severe ileocolonic CD following treatment with certolizumab pegol

Results from MUSIC trial examining endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

Placebo-controlled trials of antibiotics for maintenance of medically induced remission in Crohn's disease
Placebo-controlled trials of AZA or mercaptopurine (MP) for maintenance of medically induced remission in Crohn's disease
Placebo-controlled trials of budesonide for maintenance of medically induced remission in Crohn's disease
Placebo-controlled trials of mesalazine for maintenance of medically induced remission in Crohn's disease
Postoperative recurrence of penetrating Crohn’s disease occurs more rapidly than with stricturing Crohn’s disease

Recurrence patterns after first resection for stricturing or penetrating Crohn's disease

Progression of digestive disease damage

Development of the Crohn's disease digestive damage score, the Lémann score

RCTs of anti-TNFα including IFX, ADA & CTZ for maintenance of medically induced remission in luminal Crohn's disease
Re-operation rates for ileocolonic disease

Re-operation rates for ileocolonic disease (summary of multiple studies)

Risk factors for postoperative recurrence of Crohn’s disease after resection

Postoperative recurrence observed in high proportion of patients after resection different from ileocolon, although at lower frequency than observed after ileocolonic resection

Smokers at increased risk for first reoperation for recurrent Crohn’s disease

Risk for first reoperation for recurrent Crohn’s disease at any site for non-smokers, smokers & quitters

Smoking increases risk of disease relapse in Crohn’s disease patients

Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease

Standard growth charts (girls & boys)

Standard growth charts for girls & boys, 2-18 years (UK Department of Health)

Strictureplasty overview

Medscape article outlining types of strictureplasty

Stricturing disease behavior & weight loss at diagnosis are risk factors for developing severe Crohn’s disease

Predictors of severe Crohn's disease

Traditional corticosteroids for induction of remission in Crohn's disease (Cochrane review)

Cochrane meta-analysis finding that corticosteroids are effective for induction of remission in patients with CD, particularly when used for more than 15 weeks. 

Truelove & Witts Score

Extract from ECCO UC Consensus showing Truelove & Witts score

WELCOME study: response to induction with certolizumab pegol following infliximab failure

Response to open-label induction therapy with certolizumab pegol was achieved by 62% of patients with moderate to severely active Crohn's disease and secondary failure to infliximab.

Worldwide CD incidence rates and/or prevalence over time

Worldwide CD incidence rates and/or prevalence by country over time.

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.